EU Authorized Representative for Japanese Medical Device Manufacturers
Japanese manufacturers arrive at the MDR with something most third-country exporters do not have: membership of MDSAP and a QMS ordinance deliberately aligned with ISO 13485. Both help. Neither is recognised by a notified body, because the European Union is an observer in MDSAP rather than a participant, and because MHLW Ordinance No. 169 carries a chapter of purely Japanese requirements alongside the harmonised ones. This page sets out exactly how far the Japanese file travels and where the European work begins.
MDSAP is genuine leverage, and it stops at the Union border
Japan is one of five MDSAP members. MHLW and PMDA have participated since June 2015, PMDA has been accepting MDSAP audit reports since 2016, and the Japanese authorities have formally adopted those reports as one way of confirming conformity to Japanese QMS requirements. If your plant already holds an MDSAP certificate, a great deal of the underlying evidence — process validation, design controls, supplier management, CAPA, complaint handling — is in a shape a European auditor recognises immediately.
The stopping point is precise and worth stating plainly: the European Union sits at the MDSAP table as an Official Observer, not as a member. No MDSAP audit report discharges any obligation under Regulation (EU) 2017/745. A notified body must conduct its own quality management system assessment under Annex IX, its own technical documentation assessment, its own surveillance audits, and its own unannounced audits. Your MDSAP file shortens preparation; it does not shorten the audit.
| Element | Covered by your MDSAP audit | What MDR still requires separately |
|---|---|---|
| QMS structure and processes | Yes, against MO 169 and the other members' requirements | Annex IX Chapter I assessment by a designated notified body |
| Design and development records | Audited as a process | Product-level technical documentation assessment under Annex IX Section 4 |
| Clinical evidence | Not in scope | Clinical evaluation to Article 61 and Annex XIV, plus a PMCF plan |
| Post-market surveillance | Japanese and other member reporting rules | PMS plan, PSUR and vigilance under Articles 83 to 88 |
| Unannounced site audits | Not an MDSAP mechanism | At least once every five years under Annex IX Section 3.4 |
Shonin, Ninsho and Todokede: three doors, none of them European
Japan sorts devices into four classes and routes them through three instruments. Class I general medical devices go through todokede, a pre-market submission. Class II and some Class III controlled and specially controlled devices for which certification standards exist go through ninsho, third-party certification by a Registered Certification Body. Everything else — Class IV, and Class II or III devices without an applicable standard — goes through shonin, approval by MHLW following PMDA product review.
The instinct this builds is that someone external decides your class and hands you the applicable standard. The MDR removes that comfort. You classify your own device against the twenty-two rules in Annex VIII, using your own intended purpose wording, and you carry the consequences if you get it wrong. A JIS-referenced ninsho certification standard has no counterpart: harmonised standards under the MDR give a presumption of conformity with the general safety and performance requirements, but they never substitute for the conformity assessment route itself.
MO 169 next to ISO 13485: chapter two matches, chapter three is Japan's own
Japanese QMS requirements sit in MHLW Ministerial Ordinance No. 169 of 2004, the Ministerial Ordinance on Standards for Manufacturing Control and Quality Control for Medical Devices and In-Vitro Diagnostics. It was written in 2004 to harmonise with ISO 13485:2003, and its second chapter was revised in March 2021 to align with ISO 13485:2016, with a three-year transition that closed on 25 March 2024. PMDA publishes a clause-by-clause comparison of Chapter 2 against ISO 13485.
That alignment is the useful part. The complication is Chapter 3, which holds the additional Japanese requirements that are not in ISO 13485 at all, with further product-specific requirements in Chapters 4, 5 and 5-2. A Japanese manufacturer whose quality system was built to satisfy MO 169 in full therefore carries requirements Europe does not ask for, while lacking several the MDR does ask for: a PRRC meeting Article 15, a post-market surveillance system to Article 83 that feeds clinical evaluation, and traceability built on Basic UDI-DI and UDI-DI rather than on JMDN codes.
Where Japanese export portfolios meet the Annex VIII rules
Japan's device exports into Europe cluster in endoscopy, diagnostic imaging and ophthalmic devices, and each family lands on a different rule.
- Flexible endoscopes are reusable, invasive through a body orifice and reprocessed between patients. Reusable surgical instruments pull a notified body into an otherwise Class I route under Article 52(7), limited to cleaning, disinfection, sterilization, maintenance and functional testing.
- Imaging systems that emit ionizing radiation for diagnostic radiology, and the devices that control or monitor them, are class IIb under Annex VIII Rule 10 regardless of how routine the installed base is in Japan.
- Ophthalmic surgical products cross into Rule 8. Intraocular lenses are implants, and any device with a biological effect or that is wholly or mainly absorbed goes to class III.
Software shipped inside imaging and ophthalmic platforms is its own problem. Rule 11 puts software that informs diagnostic or therapeutic decisions in class IIa as a floor, rising to IIb or III with the severity of the decision it supports — often a class above the platform it runs on.
A Japanese MAH is not an EU Authorized Representative
Marketing Authorization Holders and registered manufacturing sites are Japanese constructs, and PMDA's accreditation of foreign manufacturers is a Japanese gate for goods entering Japan. None of it maps onto MDR roles. Under Article 11 a manufacturer not established in a Member State may place a device on the Union market only if it designates a sole authorised representative, and the designation is a mandate valid only when accepted in writing, effective at least for all devices of the same generic device group.
The mandate cannot be hollow. Article 11(3) fixes a minimum set of tasks, and Article 11(4) blocks delegation of the core manufacturer duties in Article 10. Article 11(5) then makes the representative jointly and severally liable for defective devices where the manufacturer is not established in a Member State and has not complied with Article 10 — which is why we keep a PRRC in-house, a partner of the firm with a deputy, rather than treating the role as an outsourced signature. Our EU Authorized Representative service is built around that liability, not around a mailbox.
What a Japanese package insert leaves out that Annex I Section 23 demands
Japanese labelling and package insert practice is highly disciplined and entirely single-language. The MDR requires something different in kind: "Manufacturers shall ensure that the device is accompanied by the information set out in Section 23 of Annex I in an official Union language(s) determined by the Member State in which the device is made available to the user or patient." (MDR Art. 10(11)). Twenty-four official languages, and each Member State decides which ones it insists on.
The same logic reaches the regulator-facing side. Article 11(3)(d) requires the authorised representative, on request from a competent authority, to "provide that competent authority with all the information and documentation necessary to demonstrate the conformity of a device, in an official Union language determined by the Member State concerned". A Japanese manufacturer that keeps its master records only in Japanese has a response-time problem it will not discover until an authority is already asking.
Questions from Japanese manufacturers and their MAHs
We hold MDSAP. Will a notified body accept the report instead of auditing us?
No. The EU is an Official Observer in MDSAP, not a participating member, so no report satisfies an MDR obligation. The certificate does tell a notified body that your quality system has survived a multi-jurisdiction audit, which usually means fewer findings and less remediation, but the Annex IX audit still happens in full.
Our shonin approval included clinical data. Can we reuse it?
The data, yes. The conclusion, no. Clinical evidence gathered for PMDA can feed an MDR clinical evaluation, but it has to be re-appraised against Annex XIV, mapped to your GSPR checklist, and extended with a post-market clinical follow-up plan. Japanese populations and Japanese comparator devices sometimes create equivalence gaps that only surface at this stage.
Can our Japanese MAH act as the authorised representative?
Only if it has a registered place of business in a Member State, which an MAH by definition does not. The representative must be established in the Union, be designated in writing, hold the mandate, register in EUDAMED and be reachable by every competent authority that asks. See our EUDAMED registration page for the actor and device entries that follow the mandate.
How quickly can we be listed once we appoint you?
Actor registration and SRN issuance depend on competent authority verification, not on us, so we do not promise a date. What we can do is have the mandate, the technical documentation review and the EUDAMED submission running in parallel rather than in sequence. Pricing is published and class-based, from EUR 1000 a year; see the fee table before you ask for a quotation.